

Announcement No. 11/2010

To NASDAQ OMX Copenhagen

Exiqon A/S
Skelstedet 16
2950 Vedbæk
Denmark

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR
INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA,
JAPAN OR SOUTH AFRICA

Phone: +45 4566 0888
Fax: +45 4566 1888
exiqon@exiqon.com
www.exiqon.com
CVR/Tax Id: 18 98 44 31

24 June 2010

Exiqon A/S issues 3,030,000 new shares in a directed issue

The Supervisory Board of Exiqon A/S (NASDAQ OMX Copenhagen: "EXQ") has today resolved to issue 3,030,000 new shares of DKK 1.00 nominal value at a price of DKK 6.50 per share.

The Company will receive gross proceeds of DKK 19,695,000 from the issue of the new shares.

The new shares have been allocated to institutional investors in Denmark and internationally and to certain members of the Supervisory Board in a directed issue without pre-emption rights to Exiqon's existing shareholders.

The nominal value of the share capital increase represents approximately 9.99 per cent of the Company's current nominal share capital of DKK 30,305,249. Following completion of the share capital increase, the nominal share capital of Exiqon will amount to DKK 33,335,249 divided into shares of DKK 1.00 each.

The new shares will be negotiable instruments made out in the name of the holder. There will be no restrictions in the transferability of the shares. The new shares will in every respect carry the same rights as the existing shares, including the right to receive dividends, if any, for the financial year 2010 and other rights in the Company as from the time of registration of the capital increase with the Danish Commerce and Companies Agency which is expected to take place on 29 June 2010.

Reason for the directed issue and use of proceeds

The proceeds will be used to strengthen the company's capital resources in support of the continued operations and development of the business.

Admission for trading and official listing

The new shares will be issued under temporary ISIN code DK0060238004. No application for trading and official listing has been filed for the temporary ISIN code, and the temporary ISIN code will only be registered with VP Securities A/S. The temporary ISIN code will be merged with the existing ISIN code for the existing shares, DK0060077758, as soon as possible following registration of the share capital increase with the Danish Commerce and Companies Agency, expectedly on 29 June 2010. The new shares will be admitted for trading and official listing on NASDAQ OMX Copenhagen on 1 July 2010.



Lars Kongsbak, CEO says: "With this share issue we have ensured funds that will allow us to bring new products to market and strengthen our sales in our continued efforts to bring Exiqon to profitability in 2011"

Handelsbanken Capital Markets has acted as exclusive financial adviser on this transaction.

Additional information

Lars Kongsbak, President and CEO, tel. +45 4566 0888 (cell: +45 4090 2101)

Hans Henrik Chrois Christensen, CFO, tel. +45 4566 0888 (cell: +45 4090 2131)

About Exiqon

Exiqon's products are based on the proprietary LNA™ technology. This technology offers unique advantages for detection of miRNA biomarkers for life science researchers, drug developers and cancer treating physicians working towards personalizing medicine. Exiqon operates in two business areas: Exiqon Life Sciences has established a position for itself as one of the market's leading providers of miRNA research products for miRNA analysis in cells. Our research products are used by academia, biotech and pharmaceutical companies around the world to make groundbreaking discoveries about the correlation between gene activity and the development of cancer and other diseases. Exiqon Life Sciences is also collaborating with pharmaceutical companies in their effort to develop new medicines based on miRNA as biological markers (Exiqon Pharma Services). Exiqon Diagnostics collaborates with pharmaceutical and diagnostic companies to develop novel molecular diagnostic tests for early detection of diseases which can help physicians make treatment decisions. Exiqon is listed on the NASDAQ OMX in Copenhagen. For more information about us, please visit www.exiqon.com.

Disclaimer

The securities being offered have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act") or any U.S. state securities laws, and may not be offered or sold in the United States absent registration or any applicable exemption from the registration requirement of the U.S. Securities Act and applicable U.S. state securities laws.

The information contained herein does not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities referred to herein in the United States or any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration, exemption from registration or qualification under the securities laws of any jurisdiction.

This announcement may contain forward-looking statements. These statements are based on current expectations that involve a number of risks and uncertainties which could cause actual results to differ from those anticipated. A number of factors could cause actual results and developments to differ materially from those expressed or implied by the forward-looking statements including, without limitation: conditions in the markets; the financial position, cash flows and liquidity of the Company; changing business or other market conditions; and general economic conditions. These and other factors could adversely affect the outcome and financial effects of the plans and events described in the documents or other information contained herein. Forward-looking statements contained in the documents or other information contained herein based on past trends or activities should not be taken as a representation that such trends or activities will continue in the future. Save as required by law, the Company does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. You should not place undue reliance on forward-looking statements, which are applicable only as at the date they are made.

